NVE makes magnetic sensors and data couplers. Heart implants use its sensors to switch into a safe mode.
The company · 2 · What exactly does it sell?
Almost all of it is products
Each $1 of sales, fiscal 2026
96%4%
Product salesPaid research
Paid research for customers is a small extra.
The company · 3 · How does it make money?
Very high profit on tiny sales
79%kept per $1 after making it
60%operating profit per $1
About 37%of sales to Abbott
Costs barely move with sales, so profit swings with each order.
Is it a good business? · 4 · What gives it an edge?
Regulators make a heart-implant part hard to swap
FDA
approval needed to change a safety part
Since 2006
Abbott has been buying
81,606
nerve stimulators corrected for a reed-switch fault
Once inside an approved device, a rival must persuade the maker to pay for testing and a new filing.
Is it a good business? · 5 · What is the catch?
Outside medicine the barrier is lower
Allegrosensors on the same physics
Analog Devicesdata couplers with the same pitch
Littelfuseanother sensor maker
Listed rivals: ALGM · ADI · LFUS
Its larger rivals are many times NVE's size, and its own report says prices are under pressure.
Is it a good business? · 6 · What does its record show?
Tiny, very profitable and flat
Sales, $M
27.0
38.3
29.8
25.9
26.3
31.3
Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026last 12 mo
Sales$38.3M → $31.3Msales, year to March 2023 to the past year
Profit60%operating profit per $1, fiscal 2026
Kept79%kept per $1 after making it
Sales jumped in 2023 and fell back; the profit per dollar barely changed.
Is it a good business? · 7 · How much room is there to grow?
Large markets, an unknown slice
More than 600,000industrial robots installed in 2025
328,027defibrillators implanted in 2009
No one publishes how many magnetic sensors those markets buy, so NVE's slice cannot be checked.
Is it a good business? · 8 · Who is in charge?
A research veteran became chief executive
August 2026Peter Eames became chief executive
48,371shares sold by Daniel Baker outside a plan
2.1%owned by directors and officers
Baker, chief executive since 2001, stays as chairman.
The story right now · 9 · Why do NVE's sales jump around?
Defence orders come and go
55%share jump after June's results
47%sales fall in September
2022, 2023the same pattern before
A small company's sales can jump when one big customer orders. June's jump came partly from defence orders that did not repeat.
The story right now · 10 · Why not trust June's jump?
Twice before, a big quarter faded
A big quarterShares jump.
Orders are rescheduledSales fall back.
Shares fall33.7% in a day.
The price still hopesFor June's level.
In 2022 and 2023 a big quarter lifted the shares and sales fell back. NVE blames timing and expects recovery.
The story right now · 11 · What changed lately?
Sales fell to $5.8M, wiping out June's jump
$5.83Msales, 47% below June
78.2%kept per $1 after making it, held
54.9%operating profit per $1, down
$1.00 vs $0.65dividend against earnings per share, September quarter
Weak quarter
One customer rescheduled orders and defence sales fell.
The story right now · 12 · What is everyone arguing about?
A pause, or a faded spike?
Many investors think
September was a pause after a strong June
We think
Part of June was a defence rebound that faded
Against us: NVE blames timing and expects recovery.
The price and our view · 13 · What is a share worth?
The price sits above even our best case
$56.83what we think a share is worth · the last close is of that
$56.83our value
Attractive below $45.46
Neutral
Unattractive above $68.20
$40.18gloomy: flat sales, a fifth less kept per $1
$56.83our estimate: experts' path, then slowing
$65.47sunny: flat sales, 68.6% operating profit per $1
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
The price and our view · 14 · How could we be wrong?
The spike has faded
The spike has fadedBiggest
Sales fell back.
Defence swingsShowing now
Fell again.
One big customerWatch
About 37% of sales.
The rescheduled ordersUnknown
Who, how much, when.
Bigger rivals and a dividend above profit add to the risk.
The price and our view · 15 · How will we know?
January tests pause or fade
Sales return to June's levelGood sign
Abbott orders holdGood sign
Defence sales fall againBad sign
JAN 202720
Third-quarter fiscal 2027 results, about 20 January. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.
The price and our view · 16 · So, what do we think?
A very profitable sensor maker after a faded spike
$56.83our value
Attractive below $45.46
Neutral
Unattractive above $68.20
UnattractiveHigh conviction
NVE keeps about 80 cents of each sales dollar after production costs, and its sensors in heart implants are hard to replace. But sales fell 47% in September, and the price sits above even our sunny future.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
NVE makes sensors that notice a magnet and parts that pass data between circuits without a wire joining them. Both use films a few atoms thick, made in its own Minnesota clean room.
Heart implant makers use the sensors to switch a device into a safe mode when a doctor holds a magnet over it. The older choice, a reed switch, is a tiny mechanical contact that can stick: in 2024 one maker corrected 81,606 nerve stimulators for that fault and moved to a sensor like NVE's.
How it makes money
Nearly all sales, 95.8% in fiscal 2026, are parts sold to device makers directly, through distributors and under partners' brands; the rest is paid research, mostly for defense agencies.
Because the films are made once and the factory is small, about 80 cents of each sales dollar is left after production costs. Last year NVE paid shareholders $4.00 a share, more than it earned, and the share count has not changed in six years.
Growth and profit
What growth costs
Growth costs NVE very little. Research and administration were about 18% of last year's sales, and in Q1 fiscal 2027 costs rose 50% while sales rose 81%. More sales therefore turn into more profit at a higher rate, and the reverse holds if sales fall back.
Its record
The numbers
Is it growing?Steady
Sales grew 24% over the twelve months to Jun 2026, faster than the 1.8% in the year to Mar 2026.
How steady is it?Swingy
Yearly sales growth has ranged from −22% to +42% over the last 4 years, with sales falling in 2 of them.
Are shares being diluted?Stable
The share count barely moved in 4.3 years.
Why it wins
The evidence
In a heart implant a sensor is hard to swap out. US rules require the regulator to approve any change to a component that could affect the device's safety, before it is made. Abbott filed for approval just to change the test range of the sensor in its pacemakers in 2009.
So once NVE's part is inside an approved device, a rival must persuade the maker to pay for testing and a new filing. That is why Abbott, about 37% of sales, has kept buying since 2006.
Who could beat it
The rivals in full
Outside medicine the barrier is lower. Allegro MicroSystems sells sensors built on the same physics, and Analog Devices sells data couplers with the same pitch. Both are many times NVE's size. NVE's own annual report says competition is rising, prices are under more pressure and rivals may be closing its performance lead in factory equipment.
Each rival
Allegro MicroSystems XtremeSense TMR sensorsALGM
The position, angle and speed sensing NVE sells into factory equipment and robots, from a supplier with a far larger sales force and automotive volume.
Analog Devices iCoupler isolatorsADI
NVE's IsoLoop couplers on factory networks and power converters, the data link across an isolation barrier.
Littelfuse reed switchesLFUS
The magnetic switch in an implant or instrument, where a buyer keeps the older glass reed switch instead of moving to a solid-state sensor.
How big it could get
The market and who has signed
The market
NVE sells into two large markets. A world survey counted about a million pacemakers and 328,027 defibrillators implanted in 2009, each a possible home for a sensor. Factories installed more than 600,000 industrial robots in 2025, and each robot hand and joint can use several sensors.
No one publishes how many magnetic sensors those markets buy a year, so the size of NVE's slice cannot be checked from outside.
Who has signed
Abbott buys under a supply agreement that began with St. Jude Medical in 2006 and has been amended 12 times. It runs to 31 December 2027. Every other customer orders as it goes.
Who runs it
Leaders, pay and the cash
Who runs it
Peter Eames, at NVE since 2003 and head of research and defense products, became chief executive in August 2026. Daniel Baker, chief executive since 2001, stayed as chairman.
Directors and officers own 2.1%. After the jump, Baker sold 48,371 shares outside any pre-set plan. Pay is mostly salary plus a small share of operating profit and of its increase.
What they did with the money
NVE spent about $3.4M over two years expanding its factory, finished in March 2026, and pays almost everything else out. Last year's $19.35M of dividends came partly from maturing bonds, since it was more than profit.
The last report
The latest report
NVE's sales fell to $5.8M, wiping out June's jump
What it did to the thesis Weak quarter
It failed the test we set and fell below the line that would make us doubt the case. The business is intact, but the price counted on June lasting. We cannot yet tell a pause in orders from a fade.
The report
In the three months to 30 September 2026 sales fell to $5.83M, 47% below June's $11.03M and 8% below a year earlier. NVE says one customer rescheduled orders because its stock needs changed for now, and that defense sales fell. It gives neither the customer nor the sizes.
Gross margin held at 78.2%, but operating profit fell to 54.9% of sales. Net income was $0.65 a share, and the $1.00 dividend again exceeded the quarter's earnings.
On the call, management said orders were pulled forward into June and the second half should match the first, about $8.4M a quarter. It tracks no backlog.
What's happening now
The background
The shares rose 55% the day after the June results. After the September results they fell 33.7% in a day, to $68.36 on 22 October, from $103.07. Most of the year's gain came from buyers paying more for each dollar of sales, and much of it has now gone. The retiring chief executive sold most of his shares into the rise, and short sellers hold 11.6% of the shares available to trade.
The next test is December's quarter, due about 20 January: it says whether September was a pause or the fade.
Where we disagree
Both sides in full
The market
September was a pause, but the shares have been marked down hard because June's level did not repeat.
We believe
Part of June was a defense rebound that has faded before, so the old normal is the fair base, and at 18.5 times earnings the price now pays for that.
The argument
Twice before, in 2022 and 2023, a big quarter lifted the shares and sales fell back; in September it happened again within one quarter. Defense fell 67% in fiscal 2026 before rebounding, and the retiring chief executive sold.
Against us: NVE blames timing, and on the call said sales should recover to about $8.4M a quarter in the second half; six-month sales are still up 36%. The 33% fall has taken most of the premium out of the price.
What it's worth
How we value it
Valued with sales held flat for three years, since no analyst publishes an estimate, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full.
What the price assumes
Sales growth in the first year, then slowing as ours does, at the same profit per sale.
The price assumed
12.2%
Our estimate
0%
Measured at the close of
6 Nov 2026
The three cases
Bear case$40.18
Sales stay flat, the margin settles a fifth lower at 49.9%, and new capital earns only the 8% rate: the downturn test.
Our value$56.83
Revenue is held flat for three years, since no analyst publishes an estimate (C45), then grows toward 4%, closing 30% of the gap each year; the margin moves to 62.4%, the higher of today's filed margin and its five-year average.
Bull case$65.47
Sales stay flat for three years, the margin reaches 68.6%, and new capital earns 15%.
What could go wrong
Every risk
The risks
The spike has faded
Sales fell to $5.8M in September; if December is also low, the price has little to rest on.
Defense swings
Defense sales fell 67% in fiscal 2026 and are driven by government buying cycles NVE does not control.
One big customer
Abbott is about 37% of sales, and its supply agreement runs out at the end of 2027.
Bigger rivals
In factory sensors and data couplers, much larger chip makers sell similar parts, and NVE says price pressure is rising.
Dividend above profit
NVE paid out $9.68M in six months against $9.57M of profit; if sales stay low, the cash pile shrinks or the dividend is cut.
What we still do not know
Which customer rescheduled its orders in September, how much it was, and when the orders return; no filing says.
How much of June's rise was defense and how much new products; the 10-Q gives no split.
Whether Abbott will sign again when its agreement ends in December 2027, and on what terms.
What changes our view
Every route to a new view
Every route to a new view
→ Neutral
The share price falls to about $68.20, back within 20% of what we think the business is worth.
→ Attractive
The share price falls to about $45.46, 80% of what we think the business is worth.
→ Attractive
Quarterly sales stay at or above $10.0M in both the December 2026 and March 2027 quarters. Management credits the growth mainly to non-defense products and new customers, not a defense order.
The next test
It supports the case if
Revenue at or above $8.0M, gross margin at or above 78%, and the 10-Q saying the rescheduled orders returned.
It pressures the case if
Revenue below $8.0M again, or defense sales still falling.
We would also be wrong if
Gross margin stays below 75% for two quarters while sales grow.
Dividends exceed profit again for the full fiscal year 2028.
The verdict
Scores and how we weighed it
The scores
Growth
3 of 4
Business quality
3 of 4
Financial position
4 of 4
Execution record
3 of 4
Per share capture
4 of 4
Potential
2 of 4
Risk profile
3 of 4
Valuation
1 of 4
Evidence quality
3 of 4
How we weighed it
ValueNegative
The price sits above our value and above the bull case.
BusinessPositive
Very high margins and sensors that need the regulator's approval to replace.
GrowthNegative
Sales fell back after the spike, and the value assumes no growth.
RisksNegative
The spike may have faded, defense sales swing and one customer's agreement runs out.
RivalsMixed
No filed rival compares directly, so the price is judged on its own.
The groupMixed
It sits in none of our ranked groups; medical device and defense orders move it.
Latest newsNegative
The last report failed the test we set.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.